These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 28577943)

  • 1. Uncommon EGFR mutations in advanced non-small cell lung cancer.
    O'Kane GM; Bradbury PA; Feld R; Leighl NB; Liu G; Pisters KM; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Jul; 109():137-144. PubMed ID: 28577943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
    Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor 
Receptor Mutations in Non-small Cell Lung Cancer].
    Yang X; Chen H; Zhang H; Duan J; An T; Zhao J; Zhuo M; Wu M; Wang J
    Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):493-9. PubMed ID: 26302346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
    Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
    Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.
    Klughammer B; Brugger W; Cappuzzo F; Ciuleanu T; Mok T; Reck M; Tan EH; Delmar P; Klingelschmitt G; Yin AY; Spleiss O; Wu L; Shames DS
    J Thorac Oncol; 2016 Apr; 11(4):545-55. PubMed ID: 26773740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.
    Yasuda H; Kobayashi S; Costa DB
    Lancet Oncol; 2012 Jan; 13(1):e23-31. PubMed ID: 21764376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.
    Frega S; Lorenzi M; Fassan M; Indraccolo S; Calabrese F; Favaretto A; Bonanno L; Polo V; Zago G; Lunardi F; Attili I; Pavan A; Rugge M; Guarneri V; Conte P; Pasello G
    Oncotarget; 2017 May; 8(20):32626-32638. PubMed ID: 28427238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.
    Wu TH; Hsiue EH; Lee JH; Lin CC; Yang JC
    Expert Rev Respir Med; 2017 Jan; 11(1):51-55. PubMed ID: 27927060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.
    Castellanos E; Feld E; Horn L
    J Thorac Oncol; 2017 Apr; 12(4):612-623. PubMed ID: 28017789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
    Improta G; Zupa A; Natalicchio MI; Sisinni L; Marinaccio A; Bozza G; Vita G; Aieta M; Landriscina M
    Med Oncol; 2018 Jan; 35(3):28. PubMed ID: 29387949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
    Murray S; Dahabreh IJ; Linardou H; Manoloukos M; Bafaloukos D; Kosmidis P
    J Thorac Oncol; 2008 Aug; 3(8):832-9. PubMed ID: 18670300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.
    Passaro A; Prelaj A; Bonanno L; Tiseo M; Tuzi A; Proto C; Chiari R; Rocco D; Genova C; Sini C; Cortinovis D; Pilotto S; Landi L; Bennati C; Camerini A; Toschi L; Putzu C; Cerea G; Spitaleri G; Cappuzzo F; de Marinis F
    Clin Lung Cancer; 2019 Mar; 20(2):e186-e194. PubMed ID: 30563752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.